Being a smaller biotech has its advantages and disadvantages. However, when it comes to market access, we have been able to build an efficient and fast-moving function. Even though market access in the renal therapeutic area is complex, our structure helps us handle the challenges (high treatment costs, limited options, as well as challenges in reimbursement and healthcare infrastructure) in a better way.
In this presentation you will learn:
- What advantages our smaller structure gives us?
- What can other, larger companies, learn from us?
- Agility and laser focus on what’s important – how to reach this mindset?
- How to overcome access challenges in the renal therapeutic area?
&nsbp;
